


Product Name : Icanbelimod
Cat. No. : PC-42341
CAS No. : 1514888-56-2
Molecular Formula : C₂₃H₂₄FN₃O₃
Molecular Weight : 409.4533632
Target : Lysophospholipid Receptor
Solubility :



Biological Activity

Icanbelimod (CBP-307) is a highly potent, next-generation highly potent sphingosine-1-phosphate receptor (**S1PR**) agonist with EC₅₀ of 3.55 nM (**S1PR1**), specifically targets S1PR1/4/5.

Icanbelimod (CBP-307) has significantly higher potency for S1PR1 than for S1PR4 and S1PR5, and no activity against S1PR2 and S1PR23.

Icanbelimod (CBP-307) has no notable activity for S1PR3 in Chinese hamster ovary cells expressing human S1PRs.

Icanbelimod (CBP-307) demonstrated large (> 50%) reductions in lymphocyte counts and, notably, a short elimination half-life (5.3 hours in rats) when indirectly compared with fingolimod (23.4 hours) in vivo.

Icanbelimod (CBP-307) is currently being evaluated in a global phase 2 clinical study in moderate to severe ulcerative colitis and Crohn's disease.

References

- Patent WO 2015039587 A1.
- Leiye Yu, et al. *Proc Natl Acad Sci U S A*. 2022 Apr 19;119(16):e2117716119.
- Lickliter J, et al. *Front Immunol*. 2024 Jun 17;15:1380975.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com